Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of common stock at a price to the public of $18.00 per share.
Targeting clinically validated pathways to enable patients to achieve freedom from migraine
Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones
ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growth
REX-8756 is an oral, first-in-class orthosteric STAT6 inhibitor currently being evaluated in an ongoing Phase 1 clinical study
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated
Provides corporate update including appointment of gene therapy expert Romuald Corbau, Ph.D., as Chief Scientific Officer and an update on the CNS programs
Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas
